This study will be carried on 60 participants with Type 2 Diabetes with age over 20 years.~Participants will be classified into two groups:~Group I (Interventional): treated with (NAC) dose of 1200 mg/day for two months in conjunction with conventional treatment.~Group II (Non-interventional): control group receive conventional treatment.~All patients will undergo the following:~Full medical history will be taken.~Laboratory investigations as follows:~Blood samples will be collected for analysis after overnight fasting at the beginning and after 2 months of the study for determination of:~Total cholesterol (T-chol).~Plasma triglycerides (TG).~High density lipoprotein cholesterol (HDL-C).~Low density lipoprotein cholesterol (LDL-C).~Fasting blood sugar.~Blood urea nitrogen (BUN).~Serum creatinine (SCr).~Urine analysis.~Glycated hemoglobin (HbA1c).~Lipoprotein (a). In addition, blood pressure will be measured for 24 hr.
The study is focused on the possible improving effect of N-acetylcysteine on nephropathy of type-2 diabetic patients.~Study design: Prospective clinical based study. The aim of this work is to study the effect of N-acetylcysteine (NAC) on proteinuria and on the serum level of lipoprotein a (LPa) in diabetes induced nephropathy in type-2 diabetic patients.